Redesigning the T cell: Using Synthetic Biology to Engineer Therapeutic Cells
Redesigning the T cell: Using Synthetic Biology to Engineer Therapeutic Cells
批准号:
9545542
负责人:
WENDELL A LIM
金额:
$66.13万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-23 至 2021-08-31
关键词:
Adverse effectsAntibodiesAntigensAutoimmunityBehaviorBehavior ControlCAR receptorCell CommunicationCellsClinical TrialsComplexCustomDecision MakingDiscriminationDiseaseDoseEngineeringFeedbackHybridsImmuneImmune responseImmune systemKineticsKnowledgeLeadLibrariesLightLogicMalignant NeoplasmsMemoryPatientsPharmaceutical PreparationsPhysiciansSafetyScanningSignal TransductionSignaling ProteinSiteSolid NeoplasmSpecificitySystemT cell responseT cell therapyT-Cell ActivationT-Cell ProliferationT-Cell ReceptorT-LymphocyteTherapeuticTherapeutic AgentsToxic effectTransplantationTreatment EfficacyTumor Antigensautocrinebasebehavioral responsecancer cellcancer therapycell killingcell motilitycellular engineeringchimeric antigen receptorcombinatorialcytokinecytokine release syndromecytotoxicitydesignextracellulargenetic manipulationinnovationleukemianeoplastic cellnovelprogramspublic health relevancereceptorremote controlresponsesmall moleculesuccesssynthetic biologytheoriestooltumortumor microenvironment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Engineered cells have the potential to serve as powerful "smart" therapeutic agents, but we lack a systematic framework for engineering cells to optimize their efficacy and minimize their adverse effects. For example, T cells expressing artificial tumor-directed receptors (Chimeric Antigen Receptors - CARs) have achieved unexpected success in treating certain leukemias. But the engineered cells lack the precision and control of native T cells: off-target cell killing as well as hyperactivation of the immune system lead to severe adverse effects in most patients. Achieving control over these engineered T cells remains a major challenge to making this a safe and reliable therapy that can be extended to a wider range of diseases. We propose to apply the approaches of synthetic biology to systematically engineer therapeutic immune cells with far more tailored and precisely controlled behaviors. We will apply our knowledge of cell signaling to engineer modular switches and circuits that can be used to control these therapeutic cells. Our project will span two complementary approaches, represented by the following aims: Aim 1. Develop toolbox of circuit modules for precision control of CAR T cells. We will construct modules that can be combined with CARs to increase their specificity and safety, including: a. Remote control of T cells via small molecules or light. Provide physicians with safety switches for controlling activiy of transplanted therapeutic cells. b. Tunable feedback circuits. Optimize CAR T cell responses by tuning dose-response thresholds, kinetic proofreading, and the amplitude/duration of response. c. Multi-antigen triggered activation. Increase discrimination of cancer cell targeting. d. User-guided cell migration. Target T cells to specific sites of action, increasing precision. e.
Synthetic cell-cell communication. Engineer autocrine and multi-cell decision-making circuits. Aim 2. Refactoring T cells: identify submodules in the T cell response network that can be used to construct custom response programs. Current CARs replicate the native program of T cell activation, but in response to a novel input. We postulate that there are many alternative ways to plug into the T cell signaling network and to generate custom tailored responses. We will scan combinatorial libraries of rewired T cell signaling proteins to identify alternative control points that can be activated through induced complex assembly (light or drugs). This network-rewiring library should reveal modular subnetworks that can be used as building blocks to construct custom response programs, including: a. Separate inducible control of: i) T cell proliferation, ii) tumor cell killing, and iii) memory cell establishment b. Induction of alternatie cytokine response programs ideal for cancer treatment (e.g. induce Th1 program) c. Induction of custom "a la carte" hybrid cytokine response programs that are optimized for cancer treatment.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1146/annurev-pathol-052016-100304
发表时间:
2017-01-24
期刊:
Annual review of pathology
影响因子:
--
作者:
[Esensten JH, Bluestone JA, Lim WA]
通讯作者:
Lim WA
DOI:
10.1146/annurev-immunol-051116-052302
发表时间:
2017-04-26
期刊:
Annual review of immunology
影响因子:
29.7
作者:
[Roybal KT, Lim WA]
通讯作者:
Lim WA
DOI:
10.1073/pnas.2019285118
发表时间:
2021-03-02
期刊:
Proceedings of the National Academy of Sciences of the United States of America
影响因子:
11.1
作者:
[O'Donoghue GP, Bugaj LJ, Anderson W, Daniels KG, Rawlings DJ, Lim WA]
通讯作者:
Lim WA
Engineering synthetic immune cells with modular sentinel and therapeutic functions for T1D
-
批准号:10594512
-
项目类别:
-
资助金额:$83.16万
-
财政年份:2022
-
负责人:WENDELL A LIM
-
依托单位:
Ameliorating off-target toxicities of CAR T cells by engineering NOT gates
-
批准号:10657356
-
项目类别:
-
资助金额:$44.29万
-
财政年份:2022
-
负责人:WENDELL A LIM
-
依托单位:
Ameliorating off-target toxicities of CAR T cells by engineering NOT gates
-
批准号:10362126
-
项目类别:
-
资助金额:$45.11万
-
财政年份:2022
-
负责人:WENDELL A LIM
-
依托单位:
Engineering synthetic immune cells with modular sentinel and therapeutic functions for T1D
-
批准号:10436126
-
项目类别:
-
资助金额:$83.08万
-
财政年份:2022
-
负责人:WENDELL A LIM
-
依托单位:
Recognizing the tumor ecosystem: Integrating stromal and cancer antigen signals to achieve precision recognition of solid tumors by CAR T cells
-
批准号:10094815
-
项目类别:
-
资助金额:$56.32万
-
财政年份:2020
-
负责人:WENDELL A LIM
-
依托单位:
Recognizing the tumor ecosystem: Integrating stromal and cancer antigen signals to achieve precision recognition of solid tumors by CAR T cells
-
批准号:10559489
-
项目类别:
-
资助金额:$55.2万
-
财政年份:2020
-
负责人:WENDELL A LIM
-
依托单位:
Recognizing the tumor ecosystem: Integrating stromal and cancer antigen signals to achieve precision recognition of solid tumors by CAR T cells
-
批准号:10310406
-
项目类别:
-
资助金额:$14.7万
-
财政年份:2020
-
负责人:WENDELL A LIM
-
依托单位:
Engineering synthetic helper cells that autonomously deliver orthogonal IL-2 to selectively promote therapeutic T cell proliferation in tumors
-
批准号:10285941
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2019
-
负责人:WENDELL A LIM
-
依托单位:
UCSF Center for Synthetic Immunology: Tools to Reprogram the Immune System to Combat Cancer
-
批准号:10598367
-
项目类别:
-
资助金额:$5.93万
-
财政年份:2019
-
负责人:WENDELL A LIM
-
依托单位:
UCSF Center for Synthetic Immunology: Tools to Reprogram the Immune System to Combat Cancer
-
批准号:10598362
-
项目类别:
-
资助金额:$5.93万
-
财政年份:2019
-
负责人:WENDELL A LIM
-
依托单位:
Protein Recognition in Signal Transduction
-
批准号:10460232
-
项目类别:
-
资助金额:$33.83万
-
财政年份:2018
-
负责人:WENDELL A LIM
-
依托单位:
Protein Recognition in Signal Transduction
-
批准号:10214557
-
项目类别:
-
资助金额:$34.52万
-
财政年份:2018
-
负责人:WENDELL A LIM
-
依托单位:
Redesigning the T cell: Using Synthetic Biology to Engineer Therapeutic Cells
-
批准号:9119791
-
项目类别:
-
资助金额:$66.11万
-
财政年份:2014
-
负责人:WENDELL A LIM
-
依托单位:
Redesigning the T cell: Using Synthetic Biology to Engineer Therapeutic Cells
-
批准号:9319242
-
项目类别:
-
资助金额:$66.13万
-
财政年份:2014
-
负责人:WENDELL A LIM
-
依托单位:
Redesigning the T cell: Using Synthetic Biology to Engineer Therapeutic Cells
-
批准号:8753520
-
项目类别:
-
资助金额:$68.03万
-
财政年份:2014
-
负责人:WENDELL A LIM
-
依托单位:
Harnessing CRISPR for Targeted and Inducible Epigenomic Reprogramming
-
批准号:9307796
-
项目类别:
-
资助金额:$51.35万
-
财政年份:2013
-
负责人:WENDELL A LIM
-
依托单位:
Harnessing CRISPR for Targeted and Inducible Epigenomic Reprogramming
-
批准号:8642014
-
项目类别:
-
资助金额:$50.9万
-
财政年份:2013
-
负责人:WENDELL A LIM
-
依托单位:
Harnessing CRISPR for Targeted and Inducible Epigenomic Reprogramming
-
批准号:9073782
-
项目类别:
-
资助金额:$11.98万
-
财政年份:2013
-
负责人:WENDELL A LIM
-
依托单位:
Harnessing CRISPR for Targeted and Inducible Epigenomic Reprogramming
-
批准号:8735919
-
项目类别:
-
资助金额:$51.21万
-
财政年份:2013
-
负责人:WENDELL A LIM
-
依托单位:
ELUCIDATING THE KINETIC MECHANISM OF SCAFFOLD-MEDIATED MAP KINASE SIGNALING
-
批准号:8363800
-
项目类别:
-
资助金额:$0.06万
-
财政年份:2011
-
负责人:WENDELL A LIM
-
依托单位:
海外基金